• Mashup Score: 2

    Zach Klaassen interviews Sarah Psutka about her Phase I/II trial focusing on using acupuncture to mitigate the toxic effects of Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. Psutka explains that while BCG is an essential treatment for high-risk cases, it triggers a severe inflammatory response that can lead to an array of symptoms, including urinary urgency,…

    Tweet Tweets with this article
    • Exciting research on #BladderCancer! Check out this insightful discussion with @spsutkaMD @UW and @zklaassen_md @GACancerCenter exploring the potential of #acupuncture in mitigating side effects of #BCG therapy > https://t.co/XuUfhRYWCh https://t.co/CuvqRBhtoI

  • Mashup Score: 1

    Zach Klaassen interviews Sarah Psutka about her Phase I/II trial focusing on using acupuncture to mitigate the toxic effects of Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. Psutka explains that while BCG is an essential treatment for high-risk cases, it triggers a severe inflammatory response that can lead to an array of symptoms, including urinary urgency,…

    Tweet Tweets with this article
    • Exciting research on #BladderCancer! Check out this insightful discussion with @spsutkaMD @UW and @zklaassen_md @GACancerCenter exploring the potential of #acupuncture in mitigating side effects of #BCG therapy > https://t.co/XuUfhRYWCh https://t.co/31FzQ5Jmj6

  • Mashup Score: 0

    Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.

    Tweet Tweets with this article
    • 🚨Meta-Analysis🚨 The study examined reducing BCG dose or instillations in non-muscle invasive bladder cancer patients with a literature search yielded 15 qualitative and 13 quantitative synthesis studies. #BCG #BladderCancer https://t.co/Y3BOzQkkva

  • Mashup Score: 2

    Zach Klaassen interviews Sarah Psutka about her Phase I/II trial focusing on using acupuncture to mitigate the toxic effects of Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. Psutka explains that while BCG is an essential treatment for high-risk cases, it triggers a severe inflammatory response that can lead to an array of symptoms, including urinary urgency,…

    Tweet Tweets with this article
    • Exciting research on #BladderCancer! Check out this insightful discussion with @spsutkaMD @UW and @zklaassen_md @GACancerCenter exploring the potential of #acupuncture in mitigating side effects of #BCG therapy > https://t.co/XuUfhRYWCh https://t.co/LREbU2FJLg

  • Mashup Score: 0

    iFrame is not supported! Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li Roger Li, MD – Genitourinary Oncologist – Moffitt Cancer Center It’s my pleasure to talk to you today about the updated results from the CORE1 trial combining Cretostimogene Grenadorepvec and Pembrolizumab, a…

    Tweet Tweets with this article
    • #Pembrolizumab, a groundbreaking immunotherapy drug that shows promising results in fighting non muscle invasive bladder cancer unresponsive to BCG. Watch Here: https://t.co/2ShkvYckKN @URogerLiMD @MoffitNews @UroDocASH @GarySteinbergMD #BladderCancer #BCG https://t.co/ouBi6u1wb5

  • Mashup Score: 3

    The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-GuĂ©rin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing,…

    Tweet Tweets with this article
    • For those who have reached out: yes, please feel free to use this; it was created for benefit of our patients First published in @jitcancer as @sitcancer guideline https://t.co/GZe27NRp2A Original source material from @MDAndersonNews here: #BladderCancer #MedTwitter #BCG https://t.co/Q3B0QwAO3P